Diabetes Drug Discovery: hIAPP1–37 Polymorphic Amyloid Structures as Novel Therapeutic Targets
AbstractHuman islet amyloid peptide (hIAPP1–37) aggregation is an early step in Diabetes Mellitus. We aimed to evaluate a family of pharmaco-chaperones to act as modulators that provide dynamic interventions and the multi-target capacity (native state, cytotoxic oligomers, protofilaments and fibrils of hIAPP1–37) required to meet the treatment challenges of diabetes. We used a cross-functional approach that combines in silico and in vitro biochemical and biophysical methods to study the hIAPP1–37 aggregation-oligomerization process as to reveal novel potential anti-diabetic drugs. The family of pharmaco-chaperones are modulators of the oligomerization and fibre formation of hIAPP1–37. When they interact with the amino acid in the amyloid-like steric zipper zone, they inhibit and/or delay the aggregation-oligomerization pathway by binding and stabilizing several amyloid structures of hIAPP1–37. Moreover, they can protect cerebellar granule cells (CGC) from the cytotoxicity produced by the hIAPP1–37 oligomers. The modulation of proteostasis by the family of pharmaco-chaperones A–F is a promising potential approach to limit the onset and progression of diabetes and its comorbidities. View Full-Text
Share & Cite This Article
Fernández-Gómez, I.; Sablón-Carrazana, M.; Bencomo-Martínez, A.; Domínguez, G.; Lara-Martínez, R.; Altamirano-Bustamante, N.F.; Jiménez-García, L.F.; Pasten-Hidalgo, K.; Castillo-Rodríguez, R.A.; Altamirano, P.; Marrero, S.R.; Revilla-Monsalve, C.; Valdés-Sosa, P.; Salamanca-Gómez, F.; Garrido-Magaña, E.; Rodríguez-Tanty, C.; Altamirano-Bustamante, M.M. Diabetes Drug Discovery: hIAPP1–37 Polymorphic Amyloid Structures as Novel Therapeutic Targets. Molecules 2018, 23, 686.
Fernández-Gómez I, Sablón-Carrazana M, Bencomo-Martínez A, Domínguez G, Lara-Martínez R, Altamirano-Bustamante NF, Jiménez-García LF, Pasten-Hidalgo K, Castillo-Rodríguez RA, Altamirano P, Marrero SR, Revilla-Monsalve C, Valdés-Sosa P, Salamanca-Gómez F, Garrido-Magaña E, Rodríguez-Tanty C, Altamirano-Bustamante MM. Diabetes Drug Discovery: hIAPP1–37 Polymorphic Amyloid Structures as Novel Therapeutic Targets. Molecules. 2018; 23(3):686.Chicago/Turabian Style
Fernández-Gómez, Isaac; Sablón-Carrazana, Marquiza; Bencomo-Martínez, Alberto; Domínguez, Guadalupe; Lara-Martínez, Reyna; Altamirano-Bustamante, Nelly F.; Jiménez-García, Luis F.; Pasten-Hidalgo, Karina; Castillo-Rodríguez, Rosa A.; Altamirano, Perla; Marrero, Suchitil R.; Revilla-Monsalve, Cristina; Valdés-Sosa, Peter; Salamanca-Gómez, Fabio; Garrido-Magaña, Eulalia; Rodríguez-Tanty, Chryslaine; Altamirano-Bustamante, Myriam M. 2018. "Diabetes Drug Discovery: hIAPP1–37 Polymorphic Amyloid Structures as Novel Therapeutic Targets." Molecules 23, no. 3: 686.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.